⚠️
od 10/2026 zmiany w zapisach dotyczących inhibitorów CDK4/6
Terapie w programie lekowym:
Partner
Leki w katalogu chemioterapii:
Capecitabine
Carboplatin
Cisplatinum
Cyklophosphamidum
Denosumab
Docetaxelum
Doxorubicinum
Doxorubicinum Liposomanum
Doxorubicinum Liposomanum Pegylatum
Epirubicinum
Erybulina
Etoposidum
Fluorouracilum
Fulvestrant
Gemcitabine
Ifosfamidum
Kabozantynib
Lapatinib
Methotrexatum
Nab-paclitaxel I.v.
Paclitaxel
Tamoxifenum
Trastuzumabum I.v.
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- breast cancer adjuvant
- breast cancer metastatic
- » Optimal Personalized Treatment of Early Breast Cancer Using Multi-parameter Analysis: Focus on YOUNGer Women
- » A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
- » CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
- » A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).
- » Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study